Phase I, Open-label, Single Dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics (PK) of Evobrutinib (M2951) Compared to Normal Renal Function in Male and Female Subjects

Trial Profile

Phase I, Open-label, Single Dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics (PK) of Evobrutinib (M2951) Compared to Normal Renal Function in Male and Female Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Evobrutinib (Primary)
  • Indications Autoimmune disorders; Encephalomyelitis; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Sponsors Merck KGaA
  • Most Recent Events

    • 03 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 21 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top